Ibrance

Palbociclib, the active ingredient in Ibrance, is a cyclin‑dependent kinase 4/6 (CDK4/6) inhibitor presented as an oral tablet for systemic use. It is indicated for hormone receptor‑positive, HER2‑negative advanced or metastatic breast cancer, typically in combination with endocrine therapy, and is classified as an antineoplastic agent.

GNH USA supplies Ibrance as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Ibrance is a CDK4/6 inhibitor used in the management of hormone‑driven breast cancer.

- Hormone receptor‑positive, HER2‑negative advanced breast cancer: delays disease progression when combined with endocrine therapy. - Hormone receptor‑positive, HER2‑negative metastatic breast cancer: extends progression‑free survival in patients receiving standard hormonal treatment. - Combination with endocrine therapy: enhances the effectiveness of hormonal agents in controlling tumor growth.

Common Side Effects: - Neutropenia: reduced neutrophil count, increasing infection risk. - Leukopenia: lowered white blood cell count. - Anemia: decreased red blood cells causing fatigue. - Fatigue: general tiredness and reduced stamina. - Nausea: upset stomach and urge to vomit. - Diarrhea: loose, frequent stools.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, requiring urgent care. - Pulmonary embolism: blood clot in the lungs, a medical emergency. - Severe infections: opportunistic infections due to immune suppression. - Elevated liver enzymes: potential liver injury indicated by increased ALT/AST. - QT interval prolongation: heart rhythm disturbance that may lead to arrhythmia.

Before initiating therapy, patients should be evaluated for blood‑cell counts and liver function, and monitored regularly throughout treatment.

- Monitor blood counts: perform complete blood count (CBC) before each cycle. - Assess liver function: check ALT/AST levels periodically. - Evaluate infection risk: advise patients to report fever or signs of infection promptly. - Avoid strong CYP3A4 inhibitors: drugs such as ketoconazole may increase palbociclib exposure. - Counsel on pregnancy: use effective contraception; safety in pregnancy is not established. - Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Palbociclib may interact with medicines that affect its metabolism or absorption.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise palbociclib plasma levels. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, diltiazem): may modestly increase exposure. - Antacids containing aluminum or magnesium: can affect gastrointestinal absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR as palbociclib may alter anticoagulant effect.